T-cells are real life saviors. If modified properly, they can save lupus patients from the trouble of taking medicines ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Most cancer treatments—from chemotherapies to engineered immune cells—have a host of side effects, in large part because they ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...

Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...

The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple ...

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report) today and set a ...

Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...

Researchers sought to determine whether liso-cel could be safely administered as an outpatient therapy in relapsed/refractory LBCL.